
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health is expected to experience strong growth in revenue and adjusted EBITDA in the coming years, as shown in their FY26 financial guidance. Despite potential risks from recent acquisitions, the company's integrated platform for value-based contracts and focus on the senior and chronic illness patient population suggests a promising future. However, the company's high debt load may limit their flexibility and strategic options for expansion through acquisitions and partnerships.
Bears say
Astrana Health is facing several risks including execution risk from recent M&A, elevated utilization environment, and the potential for delays in realizing expected synergies. With a forecasted EV/EBITDA multiple of 7.5x FY26 estimate, it is trading at a discount compared to the FFS hospital operator group. However, the company's strong financial model, scalable technology, and partnerships with large payers such as United Healthcare and Aetna provide potential for upside in the long-term. Investors should monitor utilization trends and execution of M&A strategy closely.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares